4-(2-((dimethylamino)methyl)morpholino)aniline | 1229980-12-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-(2-((dimethylamino)methyl)morpholino)aniline
• 英文别名: 4-{2-[(dimethylamino)methyl]morpholin-4-yl}aniline；4-[2-[(dimethylamino)methyl]morpholin-4-yl]aniline
• CAS: 1229980-12-4
• 化学式: C₁₃H₂₁N₃O
• 分子量: 235.329
• InChiKey: ATUUKRKNZKLMHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  41.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-chloro-3-(2,6-dichlorophenyl)-4-imino-1-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one 、 4-(2-((dimethylamino)methyl)morpholino)aniline 在 对甲苯磺酸 作用下， 以 正丁醇 为溶剂， 反应 0.25h， 生成 3-(2,6-dichlorophenyl)-7-[(4-{2-[(dimethylamino)methyl]morpholin-4-yl}phenyl)amino]-4-imino-1-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one
  参考文献：
  名称：

  [EN] DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE
  [FR] DÉRIVÉ DE DIHYDROPYRIMIDOPYRIMIDINE

  摘要：

  本发明涉及一种通式（I）的化合物，其中Ar1是一个可选取代的芳基或杂环芳基基团；R1是氢原子，可选取代的C1-C6烷基基团，或可选取代的芳基、芳基烷基或杂环芳基基团；R2是可选取代的芳基、芳基烷基或杂环芳基基团；R3是氢原子或C1-C6烷基基团。本发明的化合物具有出色的Wee1激酶抑制作用，因此在医学领域特别是各种癌症治疗方面非常有用。

  公开号：

  WO2010067886A1
• 作为产物：
  描述：

  N,N-dimethyl-1-(4-(4-nitrophenyl)morpholin-2-yl)methanamine 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 生成 4-(2-((dimethylamino)methyl)morpholino)aniline
  参考文献：
  名称：

  [EN] HPK1 ANTAGONISTS AND USES THEREOF
  [FR] ANTAGONISTES DE HPK1 ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用它们抑制HPK1和治疗HPK1介导的疾病的方法。

  公开号：

  WO2022213062A1

文献信息

• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060112A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及具有式（I）的新化合物，其能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE
  申请人：Bamba Makoto

  公开号：US20110243891A1

  公开（公告）日：2011-10-06

  The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar 1 is an optionally substituted aryl or heteroaryl group; R 1 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted aryl, aralkyl, or heteroaryl group; R 2 is an optionally substituted aryl, aralkyl, or heteroaryl group; and R 3 is a hydrogen atom or a C1-C6 alkyl group. A compound of the present invention has an excellent Weel kinase inhibiting effect, and is therefore useful in the filed of medicine, particularly in various types of cancer therapy.

  本发明涉及以下通式（I）的化合物等。在该式中，Ar1是一个可选取的取代芳基或杂环芳基基团；R1是氢原子，可选取的取代C1-C6烷基基团，或可选取的取代芳基、芳基烷基或杂环芳基基团；R2是可选取的取代芳基、芳基烷基或杂环芳基基团；R3是氢原子或C1-C6烷基基团。本发明的化合物具有出色的Weel激酶抑制作用，因此在医学领域，特别是各种癌症治疗中非常有用。
• Dihydropyrazolopyrimidinone derivative
  申请人：Bamba Makoto

  公开号：US08507505B2

  公开（公告）日：2013-08-13

  The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar1 is an optionally substituted aryl or heteroaryl group; R1 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted aryl, aralkyl, or heteroaryl group; R2 is an optionally substituted aryl, aralkyl, or heteroaryl group; and R3 is a hydrogen atom or a C1-C6 alkyl group. A compound of the present invention has an excellent Wee1 kinase inhibiting effect, and is therefore useful in the filed of medicine, particularly in various types of cancer therapy.

  本发明涉及一种通式（I）化合物，其中Ar1是一种可选取的取代基苯基或杂环基；R1是氢原子、一种可选取的取代基C1-C6烷基、或一种可选取的取代基苯基、芳基烷基或杂环基；R2是一种可选取的取代基芳基、芳基烷基或杂环基；R3是氢原子或一种C1-C6烷基。本发明化合物具有优异的Wee1激酶抑制作用，因此在医学领域，特别是各种类型的癌症治疗中非常有用。
• NOVEL KINASE INHIBITORS
  申请人：ORIGENIS GMBH

  公开号：US20150259340A1

  公开（公告）日：2015-09-17

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及式（I）的新型化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗各种疾病。这些疾病包括自身免疫性疾病、炎症性疾病、骨病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。